Protara Therapeutics, Inc. (NASDAQ:TARA) Major Shareholder Sells $17,570.56 in Stock

Protara Therapeutics, Inc. (NASDAQ:TARA) major shareholder Opaleye Management Inc. sold 8,288 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $2.12, for a total transaction of $17,570.56. Following the completion of the transaction, the insider now owns 87,500 shares of the company’s stock, valued at approximately $185,500. The sale was disclosed in a filing with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Opaleye Management Inc. also recently made the following trade(s):

• On Thursday, June 27th, Opaleye Management Inc. sold 46,574 shares of Protara Therapeutics stock. The shares were sold at an average price of $2.26, for a total transaction of $105,257.24.
• On Tuesday, June 25th, Opaleye Management Inc. sold 12,725 shares of Protara Therapeutics stock. The shares were sold at an average price of $2.26, for a total transaction of $28,758.50.
• On Thursday, May 30th, Opaleye Management Inc. sold 9,230 shares of Protara Therapeutics stock. The stock was sold at an average price of $2.94, for a total transaction of $27,136.20.
• On Tuesday, May 21st, Opaleye Management Inc. sold 33,000 shares of Protara Therapeutics stock. The stock was sold at an average price of $3.06, for a total transaction of $100,980.00.
• On Friday, May 17th, Opaleye Management Inc. sold 70,885 shares of Protara Therapeutics stock. The stock was sold at an average price of $3.25, for a total transaction of $230,376.25.
• On Thursday, May 9th, Opaleye Management Inc. sold 30,600 shares of Protara Therapeutics stock. The stock was sold at an average price of $3.09, for a total transaction of $94,554.00.

Protara Therapeutics Stock Up 3.4 %

Shares of TARA stock traded up $0.07 during mid-day trading on Wednesday, hitting $2.10. The stock had a trading volume of 63,257 shares, compared to its average volume of 253,507. The company’s 50-day simple moving average is $2.75 and its 200-day simple moving average is $2.96. Protara Therapeutics, Inc. has a fifty-two week low of $1.04 and a fifty-two week high of $5.24.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.02. As a group, analysts expect that Protara Therapeutics, Inc. will post -3.56 EPS for the current year.

Hedge Funds Weigh In On Protara Therapeutics

An institutional investor recently bought a new position in Protara Therapeutics stock. Oppenheimer & Co. Inc. bought a new stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) in the 1st quarter, according to its most recent 13F filing with the SEC. The firm bought 10,000 shares of the company’s stock, valued at approximately $40,000. Oppenheimer & Co. Inc. owned approximately 0.09% of Protara Therapeutics at the end of the most recent quarter. 38.13% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $23.00 target price on shares of Protara Therapeutics in a research note on Monday, May 6th. Oppenheimer raised their target price on shares of Protara Therapeutics from $26.00 to $30.00 and gave the stock an “outperform” rating in a research note on Monday, April 22nd.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.